News & Updates

MIAMI, FL — The FGC2.3: Feline Vocalization Classification and Cat Translation Project, authored by Dr. Vladislav Reznikov, has crossed a critical scientific milestone — surpassing 14,000 reads on ResearchGate and rapidly climbing toward record-setting levels in the field of animal communication and artificial intelligence. This pioneering work aims to develop the world’s first scientifically grounded…

EU, China, and more are now in the crosshairs. How’s next? It’s time to act. The Trump administration has announced sweeping tariff hikes, as high as 50%, on imports from the European Union, China, and other major markets. Affected industries? Pharmaceuticals, Biotech, Medical Devices, IVD, and Food Supplements — core sectors now facing crippling costs,…

This study presents the GDP Matrix by Dr. Vlad Reznikov, a bubble chart designed to clarify the complex relationships between GDP, PPP, and population data by categorizing countries into four quadrants—ROCKSTARS, HONEYBEES, MAVERICKS, and UNDERDOGS depending on National Regulatory Authorities (NRAs) Maturity Level (ML) of the regulatory affairs requirements for healthcare products. Find more details…

The Washington, D.C.–Baltimore area ranks in the top six for life sciences R&D and manufacturing talent, according to a CBRE report. The Maryland Department of Commerce’s director of life sciences discusses the workforce and how the state is adapting to changing needs.

Edwards recalls arterial cannulae due to risk of wire exposure that may cause serious patient harm.

HON-E-LING may be harmful due to hidden drug ingredients

The action will remove from use the very few flu shots that contain the contested preservative, elevating unproven fears it poses health risks.

While FDA Commissioner Marty Makary emphasizes learning and humility, the FDA has systematically removed the very experience that would make change possible.

The decision follows last month’s vote of the CDC’s revamped vaccine advisory committee. Thimerosal, mostly removed from vaccines decades ago, has long been a target of anti-vaccine advocates for unfounded links to autism and adverse health outcomes.

Marketing veteran Karen Todd, RD, vice president of global brand marketing at Kyowa Hakko USA, discussed the evolution of consumer awareness and messaging in the nutraceutical industry since her early career at Amway. She also highlighted a significant increase in supplement usage, driven by a more educated consumer base focused on lifestyle benefits.

TSI acknowledged that inclusion on the SSE supports China’s emphasis on high-quality, consumption-driven areas including health, wellness and advanced manufacturing.

Looking for a biopharma job in California Check out the BioSpace list of 11 companies hiring life sciences professionals like you.

Questions and answers (Q&As) on the external guidance of Policy 0070 on clinical data publication (CDP)

Dispatch seeks to address two main challenges of immunotherapies in solid tumors: the lack of a target and the immunosuppressive tumor environment.

The FDA will select at most five companies that align with national priorities, including lower drug prices and increased domestic investment.

The voluntary pauses follow two patient deaths associated with the Duchenne muscular dystrophy gene therapy.

ADARx Pharmaceuticals CEO Zhen Li found her way to biopharma through Merck, where she was inspired by the application of powerful science to human medicine.

When talking to some of the most impressive women in biopharma, the conversation inevitably turned to what these women wanted other entrepreneurs to know. Here’s the best of the best of that advice.

Baxter is removing mobile lift components due to risk of false attachment, which may result in patient injury due to falls.

FDA Commissioner’s National Priority Voucher Program. The Commissioner’s National Priority Voucher Program offers an unprecedented opportunity to reduce drug and biologic review times from 10-12 months to just 1-2 months.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV and metapneumovirus.

Tiny Health received this year’s NutraIngredients-USA Start-up of the Year award for its innovative, science-driven approach to improving child and family health through precision gut microbiome testing. The panel of expert judges recognized its strong scientific foundation, clear mission and notable commercial traction.

Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, the Duchenne patient community fears losing access to Elevidys while the regulator considers more drastic action.

BMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the agency’s decision to issue a complete response letter for Replimmune’s viral treatment RP1 for advanced melanomas. Shares of the company tumbled 75% on Tuesday.

Medline Craniotomy Kits are procedure convenience kits. Kits containing the Codman Disposable Perforator are being corrected by Medline Industries.

This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and elsewhere, as well as R&D investment.

Consumers should not to purchase or use Force Forever, a product promoted and sold for joint pain

George Tidmarsh, a Stanford University physician who founded Horizon Pharma and later ran La Jolla Pharma, was named head of the Center for Drug Evaluation and Research.

The biotech is planning to expand antisense oligonucleotide capabilities and infrastructure on campuses that already produce drugs such as the ALS therapy Qalsody.

Tidmarsh, an adjunct professor at Stanford’s medical school, brings decades of industry experience to the table. Serving as director of the Center for Drug Evaluation and Research will be his first government position.

Ritual’s entry into Ulta Beauty highlights the growing intersection of science-backed supplements and mainstream beauty retail channels.

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly lower disease exacerbation rates versus placebo in patients with chronic obstructive pulmonary disease.